Fusion Pharmaceuticals Inc.
NASDAQ:FUSN
21.55 (USD) • At close June 3, 2024
Overview | Financials
Numbers are in millions (except for per share data and ratios) USD.
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|
| Revenue
| 2.068 | 1.461 | 1.44 | 0 | 0 | 0 | 0 |
| Cost of Revenue
| 1.345 | 58.895 | 56.357 | 0.482 | 0.29 | 0 | 0 |
| Gross Profit
| 0.723 | -57.434 | -54.917 | -0.482 | -0.29 | 0 | 0 |
| Gross Profit Ratio
| 0.35 | -39.311 | -38.137 | 0 | 0 | 0 | 0 |
| Reseach & Development Expenses
| 68.758 | 58.895 | 56.357 | 17.191 | 10.632 | 6.881 | 5.366 |
| General & Administrative Expenses
| 31.197 | 30.6 | 27.098 | 20.744 | 7.588 | 3.218 | 1.62 |
| Selling & Marketing Expenses
| 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| SG&A
| 31.197 | 30.6 | 27.098 | 20.744 | 7.588 | 3.218 | 1.62 |
| Other Expenses
| 0.762 | -1.775 | 0.469 | -31.715 | -0.176 | -1.707 | 0.722 |
| Operating Expenses
| 99.955 | 89.495 | 83.455 | 37.935 | 18.044 | 9.764 | 6.986 |
| Operating Income
| -99.232 | -88.034 | -82.015 | -37.935 | -18.22 | -10.099 | -6.986 |
| Operating Income Ratio
| -47.985 | -60.256 | -56.955 | 0 | 0 | 0 | 0 |
| Total Other Income Expenses Net
| 5.122 | -1.415 | 0.85 | -37.787 | 2.282 | -1.707 | 0.722 |
| Income Before Tax
| -94.11 | -89.449 | -81.165 | -75.722 | -15.938 | -11.471 | -6.264 |
| Income Before Tax Ratio
| -45.508 | -61.225 | -56.365 | 0 | 0 | 0 | 0 |
| Income Tax Expense
| 0.787 | -1.837 | -0.118 | 2.611 | 0.251 | 0.181 | 0 |
| Net Income
| -94.897 | -87.612 | -81.047 | -78.333 | -16.189 | -11.652 | -6.264 |
| Net Income Ratio
| -45.888 | -59.967 | -56.283 | 0 | 0 | 0 | 0 |
| EPS
| -1.45 | -2 | -1.9 | -3.56 | -0.1 | -0.62 | -0.34 |
| EPS Diluted
| -1.45 | -2 | -1.9 | -3.56 | -0.1 | -0.62 | -0.34 |
| EBITDA
| -97.887 | -87.648 | -81.381 | -31.054 | -17.754 | -9.65 | -6.963 |
| EBITDA Ratio
| -47.334 | -59.992 | -56.515 | 0 | 0 | 0 | 0 |